Text Size

Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma (ASMAVIE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01078688
First received: February 25, 2010
Last updated: January 28, 2013
Last verified: January 2013
History of Changes
  Purpose

Evaluation of the frequency of limitation of activity, depending on gender and age-group, in patients with persistent asthma consulting a general practitioner


Condition
Persistent Asthma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To describe the frequency of limitations of activities in patients with persistent asthma depending on gender and age-group. [ Time Frame: Last 3 months / once ] [ Designated as safety issue: No ]
  • To describe, depending on gender and age-group, the nature of the activities limited, the degree of limitation and the impact on the patient's daily life. [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To describe the nature of the activities limited, the degree of limitation and the impact on the patient's daily life according to the level of asthma control [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]
  • To describe, depending on gender and age-group, the activities that need to be specifically investigated in routine clinical practice due to their greater impact on the patient's quality of life, and which could indicate poorly controlled asthma [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]
  • To describe the main characteristics and initial management for all patients of the survey [ Time Frame: Once during only visit ] [ Designated as safety issue: No ]

Enrollment: 1942
Study Start Date: March 2010
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First 3 consecutive patients with persistent asthma seen by general practitioner receiving long-term maintenance treatment with inhaled steroids

Criteria

Inclusion Criteria:

  • persistent asthma receiving long-term maintenance treatment with inhaled steroids (alone or in combination with other drugs)

Exclusion Criteria:

  • Patients with a diagnosis of COPD
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01078688

  Show 728 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Pascal Piedbois AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01078688     History of Changes
Other Study ID Numbers: NIS-RFR-DUM-2009/2
Study First Received: February 25, 2010
Last Updated: January 28, 2013
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Limitations of activities
persistent asthma
general practitioner
frequency of limitations of activities
depending on gender and age-group

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
 Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases

ClinicalTrials.gov processed this record on May 21, 2013